<unk> , sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).<unk>  may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of<unk>  are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite.<unk>  is a humanized Fc-modified cytolytic CD19 antibody.<unk>  was approved for medical use in the United States in July 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.<unk>  represents an option for patients ineligible for CAR-T cell therapy.
Tafasitamab
Donanemab
Atoltivimab
Naxitamab
Sutimlimab
Obiltoxaximab
Maftivimab
Regdanvimab